In the U.S. alone, there are an estimated 5 million individuals with age-related dementias. Alzheimer’s disease is one of the most common forms of dementia, possibly accounting for up to 70 percent of dementia in the elderly. Yet there are very few FDA-approved medications indicated for treating dementia. Moreover, these drugs mask the symptoms but don’t treat the underlying disease nor delay its progression.
With the aim of identifying and validating new therapeutic targets, the new SBP-GSK Center for Translational Neuroscience, located on the La Jolla campus, brings experts from SBP and GSK together to investigate factors that influence brain function and potentially slow down or reverse neurodegeneration.
Under the agreement that began in 2016, GSK is providing funding to create and support a research laboratory staffed by SBP scientists, postdoctoral fellows, and technicians who will work alongside neuroscientists from GSK.
The alliance combines the expertise of SBP scientists in fundamental neuroscience research with GSK’s proven pharmaceutical development capability and experience.